A recent study suggests that altering the guidelines for prescribing statins could potentially save thousands of lives. Researchers found that combining a statin with another drug called ezetimibe, instead of using statins alone, could be more effective in reducing “bad” cholesterol levels in patients with blocked arteries.
According to the study, this combination therapy is considered the optimal treatment for individuals who have previously experienced a heart attack. Scientists analyzed data from 14 studies involving over 100,000 high-risk patients and observed a significant 19% decrease in overall mortality when ezetimibe was added to a high-dose statin regimen to lower LDL-C levels. Additionally, cardiovascular deaths were reduced by 16%, and major adverse cardiovascular events or strokes decreased by 18% and 17%, respectively, compared to statins alone.
The combination therapy also resulted in a noteworthy 13mg per dL reduction in LDL-C levels compared to statins alone, significantly increasing the likelihood of achieving the ideal target of less than 70mg/dL. The lead author of the study, Professor Maciej Banach, emphasized the safety and efficacy of this approach, highlighting a 49% reduction in all-cause mortality and a 39% reduction in major adverse cardiovascular events compared to high-dose statin therapy alone.
The research suggests that implementing this combined therapy immediately for high-risk patients could lead to substantial reductions in cardiovascular events and deaths without the need for additional costly medications. Figures indicate that approximately 4.5 million deaths annually are linked to high LDL-C levels. If this combination therapy were universally adopted, it is estimated that over 330,000 deaths per year could be prevented among heart attack survivors globally.
Statins have a long history of safe use in lowering LDL-C by inhibiting its production in the liver, while ezetimibe works by reducing cholesterol absorption from food in the intestines. For patients who do not respond adequately to statins alone, combining ezetimibe with a statin has shown promising results. The study underscores the importance of early and aggressive treatment with combined cholesterol-lowering therapy to improve outcomes for high-risk cardiovascular patients and reduce medical complications and mortality.
